Literature DB >> 21505320

Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.

Ujjwal Neogi1, Anita Shet, Ranjani Shamsundar, Maria L Ekstrand.   

Abstract

Prevalence of etravirine genotypic resistance was assessed among 92 HIV-1C-infected patients failing nevirapine and efavirenz-based regimens from a cohort of 552 Indian patients. Overall, prevalence of etravirine cross-resistance identified using the Tibotec Weighted Score was 41% (31.5% intermediately-resistant and 9.8% fully-resistant). The most frequently described nonnucleoside reverse transcriptase inhibitor-associated mutations included Y181 (35.9%), K101 (20.7%), G190 (17.4%), and V108 (15.2%). The resistant group demonstrated higher viral load (P = 0.01) and longer duration of antiretroviral treatment (P = 0.03) compared with the susceptible group.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21505320      PMCID： PMC3637935          DOI： 10.1097/QAD.0b013e328346269f

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  24 in total

1.  Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.

Authors:  Weerawat Manosuthi; David M Butler; Wasun Chantratita; Chonlaphat Sukasem; Douglas D Richman; Davey M Smith
Journal:  AIDS Res Hum Retroviruses       Date:  2010-06       Impact factor: 2.205

2.  Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR.

Authors:  Alaka Deshpande; Valérie Jauvin; Noel Magnin; Patricia Pinson; Muriel Faure; Bernard Masquelier; Valérie Aurillac-Lavignolle; Hervé J Fleury
Journal:  AIDS Res Hum Retroviruses       Date:  2007-02       Impact factor: 2.205

Review 3.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

4.  Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India.

Authors:  Ujjwal Neogi; B S Prarthana; Soham Gupta; George D'souza; Ayesha De Costa; Vijesh Sreedhar Kuttiatt; Karthika Arumugam; Anita Shet
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-13       Impact factor: 2.205

5.  Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?

Authors:  C Scott; D Grover; M Nelson
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177

6.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.

Authors:  D D Richman; D Havlir; J Corbeil; D Looney; C Ignacio; S A Spector; J Sullivan; S Cheeseman; K Barringer; D Pauletti
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India.

Authors:  Sourav Sen; Srikanth P Tripathy; Ajit A Patil; Vaishali M Chimanpure; Ramesh S Paranjape
Journal:  AIDS Res Hum Retroviruses       Date:  2007-10       Impact factor: 2.205

8.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christine Katlama; Arend Moll; William Towner; Benoit Trottier; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Benny Baeten; Greet Beets; Rekha Sinha; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

9.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  José Valdez Madruga; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob Lalezari; Anthony Mills; Gilles Pialoux; Timothy Wilkin; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Lorant Leopold; Roberta Trefiglio; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

10.  Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India.

Authors:  Sourav Sen; Srikanth P Tripathy; Vaishali M Chimanpure; Ajit A Patil; Rajani D Bagul; Ramesh S Paranjape
Journal:  AIDS Res Hum Retroviruses       Date:  2007-04       Impact factor: 2.205
View more
  14 in total

1.  Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.

Authors:  Eugene L Asahchop; Mark A Wainberg; Richard D Sloan; Cécile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

2.  Pretreatment HIV drug resistance among adults initiating ART in Namibia.

Authors:  Negussie Taffa; Clay Roscoe; Souleymane Sawadogo; Michael De Klerk; Andrew L Baughman; Adam Wolkon; Nicholus Mutenda; Josh DeVos; Du-Ping Zheng; Nick Wagar; Dimitri Prybylski; Chunfu Yang; Ndapewa Hamunime; Simon Agolory; Elliot Raizes
Journal:  J Antimicrob Chemother       Date:  2018-11-01       Impact factor: 5.790

3.  In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.

Authors:  Susan M Schader; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Susan P Colby-Germinario; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

4.  Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.

Authors:  Duncan T Njenda; Shambhu G Aralaguppe; Kamalendra Singh; Rohit Rao; Anders Sönnerborg; Stefan G Sarafianos; Ujjwal Neogi
Journal:  J Antimicrob Chemother       Date:  2018-10-01       Impact factor: 5.790

Review 5.  The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.

Authors:  Mark A Wainberg
Journal:  Scientifica (Cairo)       Date:  2012-12-31

6.  Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.

Authors:  Jason V Baker; Kathleen Huppler Hullsiek; Rachel Prosser; Daniel Duprez; Richard Grimm; Russell P Tracy; Frank Rhame; Keith Henry; James D Neaton
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

7.  Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study.

Authors:  Ujjwal Neogi; Elsa Heylen; Anita Shet; Sara Chandy; Ranjani Shamsunder; Anders Sönnerborg; Maria L Ekstrand
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

8.  High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naïve perinatally-infected children and adolescents with HIV-1 subtype C infection.

Authors:  Ujjwal Neogi; Pravat Nalini Sahoo; Ayesha De Costa; Anita Shet
Journal:  BMC Infect Dis       Date:  2012-11-22       Impact factor: 3.090

9.  Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India.

Authors:  Snigdha Vallabhaneni; Sara Chandy; Elsa Heylen; Maria L Ekstrand
Journal:  J Int AIDS Soc       Date:  2013-06-03       Impact factor: 5.396

10.  Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.

Authors:  Ujjwal Neogi; Anita Shet; Pravat Nalini Sahoo; Irene Bontell; Maria L Ekstrand; Akhil C Banerjea; Anders Sonnerborg
Journal:  J Int AIDS Soc       Date:  2013-02-25       Impact factor: 5.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.